Transaction DateRecipientSharesTypePriceValue
30th September 2020Robert J. Spiegel4,130Grant/award etc.$0.00
15th September 2020Gregory Gene Freitag13,046Exercise of derivative$3.67$47,878.82
8th September 2020Andrew Saik40,000Open or private purchase$1.46$58,480.00
27th August 2020Rosemary A Crane661Grant/award etc.$0.00
11th August 2020Rosemary A Crane2,860Open or private sale$11.90$34,037.72
11th August 2020Sol J Barer23,133Exercise of derivative$0.00
11th August 2020Rosemary A Crane7,956Exercise of derivative$0.00
30th June 2020Robert J. Spiegel3,297Grant/award etc.$0.00
11th June 2020Sol J Barer31,388Exercise of derivative$0.00
11th June 2020Rosemary A Crane17,621Exercise of derivative$0.00
Edge Therapeutics
Edge Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


is a biotechnology company which develops therapies. It is based in San Francisco and has offices in New York and London. The company has been in business for more than 30 years.


Ticker: EDGE
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1472091
Employees: 10
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals